Skip to main content

Lonza swings to pharma

29th January 2020

Submitted by:

Andrew Warmington

Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future. The company also revealed that it will be seeking a new CEO specifically from the pharma and biotech arena.

In 2019, sales were 6.8% up on 2018 at CHF 5.9 billion and core EBITDA was CHF 1.6 billion, a 27.4% margin, despite heavy ongoing investment in growth projects. Within this Pharma Biotech & Nutrition had 11.0% growth to CHF 4.2 billion and achieved a core EBITDA of CHF 1.4 billion, with a margin of 32.9%.

Among many other highlights, Lonza noted that the small molecules business “continued to benefit from innovative business models, formulation and encapsulation capabilities”. The highly potent APIs “made a positive contribution”, with customers including AstraZeneca signing new long-term contracts and another contract being signed for drug substance payloads ADCs. Mammalian and microbial activity “saw ongoing strong momentum for its clinical and commercial offerings”, the company said, while its integrated clinical service offerings “gained traction”.

There are a large number of investment projects going on. In 2019, the company spent 13.3% of group sales, CHF 786 million, on capex in areas including HPAPIs and bioconjugates, clinical and commercial biologics, mid-scale and clinical-scale mammalian, cell and gene and drug product services. A similar level of capex is expected in 2020, with at least more significant projects scheduled to start operations by the end of the year.

By contrast, said chairman Albert Baehny, Lonza Specialty Ingredients (LSI) had a “soft full-year performance after headwinds”. It sales fell 3.2% fall in sales to CHF 1.7 billion although the core EBITDA improved to CHF 302 million and the margin improved to 17.8%, thanks to productivity gains, cost control measures and price increases. Lonza is carving out LSI under the Outlook 2020 project and this is on schedule to be completed in mid-2020.

Performance for LSI in 2019 was very mixed. Overall demand for its core microbial control offer was said to be “solid” but demand fluctuated from mark to market. Home care disinfection and professional hygiene were strong, while personal care ended the year soft after an uptick in 2H, thanks to increasing demand for Lonza's anti-dandruff platform for hair care in Europe.

Wood protection, oil and gas, and paints and coatings were also strong, but the polymer and textile sector was hit by weak automotive industry demand and supply disruption for a key BIT intermediate. Crop protection faced many headwinds and the speciality chemicals business was particularly hit by such headwinds as the impact of the US-China trade war on the already difficult consumer electronics market.

It was also revealed in the results presentation that the Nomination & Compensation Committee is searching for a new CEO, Marc Funk having resigned in March after only eight months at the helm. Christoph Mäder will remain as ‘lead independent director’ until this process is completed, which is expected to be during 2020. Baehny has suggested that the new CEO should be someone with at least two decades of experience in pharma or biotech, including bioprocesses, to bioproducts. According to Reuters, inteviews with six shortlisted candidates should begin shortly.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington